Pulmonx(US:LUNG) ZACKS·2025-07-30 23:01Core Insights - Pulmonx Corporation reported a quarterly loss of $0.38 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.40, and compared to a loss of $0.39 per share a year ago, indicating an earnings surprise of +5.00% [1] - The company achieved revenues of $23.86 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.25% and showing an increase from $20.78 million in the same quarter last year [2] - Pulmonx shares have declined approximately 54.5% year-to-date, contrasting with the S&P 500's gain of 8.3% [3] Financial Performance - Over the last four quarters, Pulmonx has exceeded consensus EPS estimates four times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.39 on revenues of $23.49 million, and for the current fiscal year, it is -$1.52 on revenues of $97.19 million [7] Market Outlook - The company's earnings outlook will be crucial for future stock performance, with management's commentary on the earnings call expected to influence investor sentiment [3][4] - The Zacks Rank for Pulmonx is currently 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical Info Systems industry, to which Pulmonx belongs, is currently ranked in the top 23% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Hims & Hers Health, Inc., is expected to report a quarterly earnings increase of +200% and revenues of $551.84 million, up 74.8% from the previous year [9][10]